January 3, 2023

Revenue for Rybelsus by Novo Nordisk is expected to have a CAGR of 5.78% through 2038. How does that impact the rNPV of the drug?

Rybelsus is a Recombinant Peptide owned by Novo Nordisk, and is involved in 72 clinical trials, of which 42 were completed, 26 are ongoing, and 4 are planned.

Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme

OG-217SC (oral semaglutide) is a GLP1R agonist. GLP-1 (glucagon-like peptide-1) is a natural hormone involved in controlling blood sugar levels. Upon GLP-1 receptor activation, adenylyl cyclase is activated and cAMP is generated, leading in turn, to short-term effect of enhancing glucose-induced insulin secretion. The continuous GLP-1 receptor activation also increases insulin synthesis and beta cell proliferation and neogenesis. The drug candidate reduces blood sugar by enhancing glucose-dependent insulin secretion from the pancreas.

The revenue for Rybelsus is expected to reach a total of $93.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rybelsus NPV Report.

Rybelsus is originated and owned by Novo Nordisk.

Rybelsus Overview

Semaglutide (Rybelsus) is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 produced by yeast fermentation, acts as an anti-diabetic agent. It is formulated as tablets for oral route of administration. Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Rybelsus is also indicated in reducing the risk of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Rybelsus is under development for the treatment of type 2 diabetes in China.

Novo Nordisk Overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

The company reported revenues of (Danish Krone) DKK140,800 million for the fiscal year ended December 2021 (FY2021), an increase of 10.9% over FY2020. In FY2021, the company’s operating margin was 41.7%, compared to an operating margin of 42.6% in FY2020. In FY2021, the company recorded a net margin of 33.9%, compared to a net margin of 33.2% in FY2020. The company reported revenues of DKK45,566 million for the third quarter ended September 2022, an increase of 10.4% over the previous quarter.

Quick View – Rybelsus

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Rybelsus
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.

Recommended Reports

View All

Companies Intelligence

View All